The age-related macular degeneration (AMD) market in the UK, US, France, Germany, Italy, Spain and Japan was forecast to grow from $7.4bn in 2021 to $27.5bn in 2031.
Growth, according to the analytics company GlobalData, was driven by the launch of longer-acting anti-vascular endothelial growth factor (anti-VEGF) therapies, an increase in the number of people with AMD and the availability of therapies for geographic atrophy (GA).
GlobalData’s latest report, Age-related macular degeneration: seven-market drug forecast and market analysis, revealed that anti-VEGF therapies will continue to remain the dominant treatment modality for AMD during the forecast period.
Sara Reci, senior analyst at GlobalData, said: “In interviews with GlobalData, key opinion leaders emphasised that the greatest unmet needs in the AMD space included the need for longer-acting anti-VEGF therapies, treatment for GA, less invasive drug formulations, early diagnosis of patients and increasing awareness of AMD, and availability or accessibility of specialists and patient wait times.’